|
Re: New hope
Hi
Just read this on smartpatients.com. Never heard of it until today!
RO6874281
A monoclonal antibody directed against fibroblast activation protein-alpha (FAP) linked to an engineered, variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities.
I'm currently on a trial with Kadcyla and Atezolizumab (Tecentriq). Atezolizumab is being paired with this new drug R06874281 in other trials.
Lets hope it has great results.
Juls
|